[Cancer immunotherapy targeting WT1 product which overexpressess in various kinds of malignant neoplasms].
Oka
Yoshihiro
Y
yoshi@imed3.med.osaka-u.ac.jp
Tsuboi
Akihiro
A
Sugiyama
Haruo
H
D000818:Animals; D000912:Antibodies, Neoplasm; D000917:Antibody Formation; D019496:Cancer Vaccines; D017321:Clinical Trials, Phase I as Topic; D006801:Humans; D007111:Immunity, Cellular; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D007134:Immunoglobulin Switch Region; D007167:Immunotherapy / Q000379:methods*; D016233:Immunotherapy, Active; D051379:Mice; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D025721:WT1 Proteins / Q000276:immunology
D000912:Antibodies, Neoplasm; D019496:Cancer Vaccines; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D025721:WT1 Proteins